Combination therapies: inhibitors of GABA transaminase and NKCC1
Inhibitors of NKCC1, such as bumetanide, when coadministered with inhibitors of GABA transaminase, such as vigabatrin, attenuate both the retinal toxicity and the intramyelinic edema.
1. A method of attenuating a retinal toxicity or an intramyelinic edema side effect of vigabatrin therapy comprising co-administering to a person in need thereof an effective amount of vigabatrin and bumetanide.
2. The method of claim 1 wherein the person is determined to have had infantile spasms or refractory seizures as an adult.
3. The method of claim 1 , wherein vigabatrin and bumetanide are administered to the person in a single dosage form.
4. The method of claim 1 , wherein the person is administered a dosage form of vigabatrin and a dosage form of bumetanide.
5. The method of claim 1 , wherein the person is administered a dose of 50mg/kg to 150 mg/kg vigabatrin.
6. The method of claim 1 , wherein the person is administered a dose of 0.1mg/kg to 0.2 mg/kg bumetanide.
7. The method of claim 1 , wherein the person is administered a dose of 50mg/kg to 150 mg/kg vigabatrin and a dose of 0.1 mg/kg to 0.2 mg/kg vigabatrin.
8. The method of claim 4 , wherein the dosage form of vigabatrin contains 100mg to 1000 mg of vigabatrin and the dosage form of bumetanide contains 0.2 mg to 3.0 mg bumetanide.
9. The method of claim 8 , wherein the dosage form of vigabatrin contains 200mg to 800 mg vigabatrin and the dosage form of bumetanide contains 0.2 mg to 0.5 mg bumetanide.
10. The method of claim 8 , wherein the dosage form of vigabatrin contains 500mg vigabatrin.
11. The method of claim 9 , wherein the dosage form of vigabatrin contains 500mg vigabatrin.